LinkedIn Profile

Access Neuronax SAS historical Linkedin company profile data on number of followers, employee headcount and more

Records

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:neuronaxsas-2 1377992 May 30th, 2019 12:00AM NEURONAX 272 4.00 Open Pharmaceuticals May 30th, 2019 01:45PM May 30th, 2019 01:45PM NEURONAX is a privately-held biotech company focusing on the development of candidate-drugs for the treatment of traumatic or severe degenerative disorders of the central nervous system (CNS). NEURONAX focuses particular nervous disorders for which the capacities to treat patients are limited and the "unmet needs"​ are very important. Among them, injuries of the CNS are among the major clinical problems since the consequences are currently irreversible resulting in serious disabilities in sensory and motor function. Our most advanced product candidate, NX210, a neuro-protective and neuro-regenerative peptide, was deduced from a naturally secreted protein produced early during emryonic development by specialized ependymal cells located in the brain. This promising first-in-class candidate has been shown to improve recovery and neurological function and may adress treatment of various acute and chronic disorders, including but not limited to spinal cord injuries (SCI), traumatic brain injuries (TBI), stroke, Alzheimer or Parkinson’s diseases. For more information, please visit our website. Open neural repair, neuroprotection, spinal cord injury, neurodegenerative diseases, candidate-drug, preclinical, neuroregeneration, peptide, traumatic brain injury, stem cells, axon outgrowth Open 60 avenue Rockefeller Lyon FR 69008 Pharmaceuticals & Biotechnology
private:neuronaxsas-2 1377992 Nov 7th, 2017 12:00AM NEURONAX 170 5.00 Open Pharmaceuticals Nov 7th, 2017 05:28PM Nov 7th, 2017 05:28PM NEURONAX is a privately-held biotech company focusing on the development of candidate-drugs for the treatment of traumatic or severe degenerative disorders of the central nervous system (CNS). NEURONAX focuses particular nervous disorders for which the capacities to treat patients are limited and the "unmet needs"​ are very important. Among them, injuries of the CNS are among the major clinical problems since the consequences are currently irreversible resulting in serious disabilities in sensory and motor function. Our most advanced product candidate, NX210, a neuro-protective and neuro-regenerative peptide, was deduced from a naturally secreted protein produced early during emryonic development by specialized ependymal cells located in the brain. This promising first-in-class candidate has been shown to improve recovery and neurological function and may adress treatment of various acute and chronic disorders, including but not limited to spinal cord injuries (SCI), traumatic brain injuries (TBI), stroke, Alzheimer or Parkinson’s diseases. For more information, please visit our website. Pharmaceuticals & Biotechnology
private:neuronaxsas-2 1377992 Nov 1st, 2017 12:00AM NEURONAX 168 4.00 Open Pharmaceuticals Nov 1st, 2017 05:10AM Nov 1st, 2017 05:10AM NEURONAX is a privately-held biotech company focusing on the development of candidate-drugs for the treatment of traumatic or severe degenerative disorders of the central nervous system (CNS). NEURONAX focuses particular nervous disorders for which the capacities to treat patients are limited and the "unmet needs"​ are very important. Among them, injuries of the CNS are among the major clinical problems since the consequences are currently irreversible resulting in serious disabilities in sensory and motor function. Our most advanced product candidate, NX210, a neuro-protective and neuro-regenerative peptide, was deduced from a naturally secreted protein produced early during emryonic development by specialized ependymal cells located in the brain. This promising first-in-class candidate has been shown to improve recovery and neurological function and may adress treatment of various acute and chronic disorders, including but not limited to spinal cord injuries (SCI), traumatic brain injuries (TBI), stroke, Alzheimer or Parkinson’s diseases. For more information, please visit our website. Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.